Home›Research›Compare›Eloralintide vs Semaglutide
Peptide ComparisonEloralintide vs Semaglutide
Both are Metabolic peptides.
Eloralintide
LY3841136
Half-life: Not published
1 providers listed
Semaglutide
GLP-1
Half-life: ~7 days (once-weekly dosing)
806 providers listed
Semaglutide is FDA-approved, while Eloralintide is investigational — the clearest structural difference between them.
Eloralintide
Half-life
Not published
Semaglutide
Half-life
~7 days (once-weekly dosing)
| Your goal | Better option |
|---|---|
| Further along in FDA review | Semaglutide |
| Oral administration option | Semaglutide |
| More provider options (1 vs 806) | Semaglutide |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
Eloralintide
Semaglutide
Eloralintide
Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A N…
Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of con…
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentr…
Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to cli…
Semaglutide
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Obstetrical and medical outcomes following GLP-1 receptor agonist exposure in pregnancy: a case series.
+1 more
About Eloralintide
Selective long-acting amylin receptor agonist; preferentially activates AMY1R over the calcitonin receptor to prolong satiety and slow gastric emptying
About Semaglutide
Semaglutide is a GLP-1 receptor agonist that mimics the incretin hormone GLP-1, stimulating glucose-dependent insulin secretion, suppressing glucagon release, and slowing gastric emptying. Central GLP-1 receptor activation in the hypothalamus and brainstem reduces appetite and caloric intake. Its extended half-life of approximately seven days is achieved via structural modifications including a C18 fatty diacid chain enabling reversible albumin binding.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Eloralintide
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
No amylin-specific monitoring protocol is established for eloralintide, which remains investigational and is available only through clinical trials. Trial programmes track a baseline metabolic panel covering glycaemic markers, renal and hepatic function, and lipase. Calcitonin and TSH are carried over from incretin-class convention rather than from any eloralintide-specific signal, as the compound is designed for reduced calcitonin receptor activity.
Semaglutide
Risk of thyroid C-cell tumors (dose- and duration-dependent in rodents; human relevance undetermined).
Source: FDA label
FDA prescribing protocols track HbA1c and fasting glucose for glycemic response, calcitonin for thyroid C-cell risk (black box warning), and lipase for pancreatitis screening. Baseline renal and hepatic panels are standard.
Eloralintide
Not enough vendor pricing yet.
Semaglutide
Where to source these peptides
Eloralintide
1 listed
Browse directory →
Providers offeringSemaglutide
806 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Metabolic Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated August 26, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). Eloralintide vs Semaglutide — Per-mg Price Comparison. Retrieved September 11, 2026, from https://peptidebase.io/peptides/compare/eloralintide/semaglutide